In Juno patient deaths, echoes seen of earlier failed company
By Sharon Begley,
STAT
| 07. 08. 2016
Two top executives and dozens of other employees of Juno Therapeutics, the company that on Thursday was forced to halt a clinical trial after three leukemia patients died, are alumni of another biotech company that declared bankruptcy two years ago after disappointing sales of its one product.
And the roots of both Seattle companies’ troubles appear similar to some close observers: a failure to adequately heed the scientific challenges of bringing complicated cancer immunotherapies to market.
“There are echoes here of [the previous company,] Dendreon,” said a health care industry analyst who declined to be named because of concerns it would hurt client relationships. “Both companies were willing to move ahead with something when they had only a superficial, almost cartoonish, understanding of how [the experimental therapy] works at the cellular level. And now three people are dead. … It’s beyond tragic.”
Continue reading on STAT
Image via Pexels
Related Articles
A Review of Exposed by Becky McClain
“Do not get lost in a sea of despair. Be hopeful, be optimistic. Our struggle is not the struggle of a day, a week, a month, or a year, it is the struggle of a lifetime. Never, ever be afraid to make some noise and get in good trouble, necessary trouble.”
— John Lewis
Becky McClain became famous when she successfully sued Pfizer, one of the very largest pharmaceutical and biotech companies. She...
By staff, Japan Times | 12.04.2025
Japan plans to introduce a ban with penalties on implanting a genome-edited fertilized human egg into the womb of a human or another animal amid concerns over "designer babies."
A government expert panel broadly approved a proposal, including the ban...
By Katherine Long, Ben Foldy, and Lingling Wei, The Wall Street Journal | 12.13.2025
Inside a closed Los Angeles courtroom, something wasn’t right.
Clerks working for family court Judge Amy Pellman were reviewing routine surrogacy petitions when they spotted an unusual pattern: the same name, again and again.
A Chinese billionaire was seeking parental...
By Sarah A. Topol, The New York Times Magazine | 12.14.2025
The women in House 3 rarely had a chance to speak to the women in House 5, but when they did, the things they heard scared them. They didn’t actually know where House 5 was, only that it was huge...
